Thu, October 15, 2009
Wed, October 14, 2009
Tue, October 13, 2009
Mon, October 12, 2009
Fri, October 9, 2009
Thu, October 8, 2009
Wed, October 7, 2009
Tue, October 6, 2009
Mon, October 5, 2009
Sun, October 4, 2009
Fri, October 2, 2009
Thu, October 1, 2009
Wed, September 30, 2009
Tue, September 29, 2009
Mon, September 28, 2009
Fri, September 25, 2009
Thu, September 24, 2009
Wed, September 23, 2009
Tue, September 22, 2009
Mon, September 21, 2009
Fri, September 18, 2009
Thu, September 17, 2009
Wed, September 16, 2009
Tue, September 15, 2009
Mon, September 14, 2009
Fri, September 11, 2009
Thu, September 10, 2009
Wed, September 9, 2009
Tue, September 8, 2009
Sun, September 6, 2009
Fri, September 4, 2009
Thu, September 3, 2009
Wed, September 2, 2009
Tue, September 1, 2009
Mon, August 31, 2009
Fri, August 28, 2009
Thu, August 27, 2009
Wed, August 26, 2009
Tue, August 25, 2009
Mon, August 24, 2009
Sun, August 23, 2009
Fri, August 21, 2009

BiomedReports.Com: CEL-SCI's CEO Says H1N1 Flu Drug Candidate Could Propel Company Onto World Stage


//health-fitness.news-articles.net/content/2009/ .. idate-could-propel-company-onto-world-stage.html
Published in Health and Fitness on Friday, September 18th 2009 at 11:49 GMT by Market Wire   Print publication without navigation


LOS ANGELES, CA--(Marketwire - September 18, 2009) - BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a transcript of their interview with CEL-SCI Corporation's CEO, Geert Kersten.

CEL-SCI Corporation's (NYSE Amex: [ CVM ]) just received FDA approval to proceed with a clinical trial of its H1N1 flu drug candidate, testing its effect on white blood cells of patients who are hospitalized. The biotech firm said it is working on the next phase of the study and is preparing the drug's follow-up regulatory application.

"You have to consider that the 'bad' evolution of this virus is most likely to happen outside of this country," says Kersten. "That's where you're going to get re-assortment. We don't know what those death rates could be, but what you have from the current virus is high transmissibility in warm weather which has not been seen before in any other flu virus. If it picks up something nasty from another virus and that person gets on a plane, well then suddenly CEL-SCI could be the most important company in the world because there will be no one else who has done any work on this at all. Everyone would come to us."

The complete transcript is available now at BioMedReports.Com:

[ http://biomedreports.com/component/content/article/56-top-leading-news/10089-ceo-other-countries-may-also-want-cel-scis-h1n1-treatment.html ]

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

[ http://biomedreports.com/fda-calendar/fda-calendar.html ]

For more biomedical sector and investment news go to[ http://BioMedReports.com ]


Publication Contributing Sources

Similar Health and Fitness Publications